title: Comparison of nail lacquer clobetasol efficacy at 0.05%, 1% and 8% in nail psoriasis treatment: prospective, controlled and randomized pilot study.
abstract: BACKGROUND
  Nail psoriasis may affect up to 90% of patients with psoriasis in the course of the disease throughout their lives and it is often a therapeutic challenge to dermatologists. Topical treatments described in the literature have demonstrated variable efficacy, and unsatisfactory results have been associated to inefficient penetration of the active ingredient into the nail plate and proximal nail fold. Recently the use of clobetasol on nail lacquer vehicle has been suggested, with satisfactory results and no side effects.
  
  
  OBJECTIVE
  To determine the efficacy and safety of clobetasol in nail lacquer vehicle in three concentrations (0.05%, 1% and 8%) in patients with nail psoriasis.
  
  
  METHODS
  Prospective, controlled, randomized pilot study in fifteen patients with nail bed and/or nail matrix psoriasis in both hands, subdivided into three groups: A(0.05% clobetasol nail lacquer), B(1% clobetasol nail lacquer) and C(8% clobetasol nail lacquer). All groups used clobetasol nail lacquer on the left hand and base coat nail lacquer as control on the right, twice a week for 16 weeks. Clinical evaluation was done by photographic records and the NAPSI score of both treated and control hands, as well as modified NAPSI score of the most affected nail of the treated hand.
  
  
  RESULTS
  Group C showed a statistically relevant clinical response compared to the other groups, reflected in the improvement of clinical parameters, of treated hand NAPSI score, when compared to the control hand, and modified NAPSI score of the most affected nail in the treated hand.
  
  
  CONCLUSIONS
  The 8% clobetasol nail lacquer was effective and safe, and it can be considered a good option of topical therapy in the treatment of nail psoriasis.
authors.affiliation: Centro de Estudos da Unha, Instituto de Dermatologia Professor Rubem David Azulay, Santa Casa da Misericórdia do Rio de Janeiro, Rio de Janeiro, RJ, Brazil. robertha_nakamura@yahoo.com.br
authors.forename: Robertha Carvalho
authors.initials: RC
authors.lastname: Nakamura
authors.forename: Luciana de
authors.initials: Ld
authors.lastname: Abreu
authors.forename: Bruna
authors.initials: B
authors.lastname: Duque-Estrada
authors.forename: Carla
authors.initials: C
authors.lastname: Tamler
authors.forename: Andreia Pizarro
authors.initials: AP
authors.lastname: Leverone
mesh_terms: D000287:Administration, Topical; D000328:Adult; D000368:Aged; D002990:Clobetasol / Q000008:administration & dosage*; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage*; D006229:Hand Dermatoses / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009260:Nail Diseases / Q000188:drug therapy*; D017060:Patient Satisfaction; D010865:Pilot Projects; D011446:Prospective Studies; D011565:Psoriasis / Q000188:drug therapy*
chemical_list: D005938:Glucocorticoids; D002990:Clobetasol